Comparative Pharmacology
Head-to-head clinical analysis: BREO ELLIPTA versus M PREDROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREO ELLIPTA versus M PREDROL.
BREO ELLIPTA vs M-PREDROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of fluticasone furoate, a corticosteroid that binds to glucocorticoid receptors to inhibit inflammatory gene transcription, and vilanterol, a long-acting beta2-adrenergic agonist that activates adenylate cyclase leading to bronchodilation.
Methylprednisolone is a glucocorticoid receptor agonist. It binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of pro-inflammatory cytokines, chemokines, and adhesion molecules. It also inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis.
One inhalation (100 mcg fluticasone furoate / 25 mcg vilanterol) once daily via oral inhalation.
4 to 48 mg/day orally or intramuscularly in divided doses every 12 hours; for acute conditions, up to 120 mg/day intravenously in divided doses every 4-6 hours.
None Documented
None Documented
Fluticasone furoate: 24 hours (supports once-daily dosing). Vilanterol: 11 hours (supports once-daily dosing).
Terminal elimination half-life: 2–4 hours. Clinical context: shorter than other corticosteroids; requires multiple daily doses for sustained anti-inflammatory effect.
Fluticasone furoate is eliminated primarily via fecal excretion (approximately 101% of an oral dose) due to biliary clearance, with minimal renal excretion (<1%). Vilanterol is eliminated via metabolism and subsequent renal (approximately 70% of an IV dose) and fecal (approximately 30% of an IV dose) excretion.
Primarily hepatic metabolism; <20% excreted unchanged in urine. Negligible biliary/fecal elimination.
Category C
Category C
Corticosteroid/Beta-2 Agonist Combination
Corticosteroid